Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Lerner, D. M. Articles by Rosenstein, D. L. Search for Related Content PubMed Citation Articles by Lerner, D. M. Articles by Rosenstein, D. L. Other Treatment Other Neuroscience

Neuropsychiatric Toxicity Associated With Cytokine Therapies

Received December 12, 1998; accepted January 11, 1999. From the Experimental Therapeutics Branch, National Institute of Mental Health, Bethesda, MD. Address correspondence and reprint requests to Dr. Lerner, Experimental Therapeutics Branch, Building 10, Room 3N218, 10 Center Drive, MSC 1274, National Institute of Mental Health, Bethesda, MD 20892–1274.

The cytokines interleukin-2 and interferon- are potent biological agents used to treat malignancy, infectious diseases, and neurodegenerative disorders. While these medications show substantial therapeutic promise, the neuropsychiatric toxicity associated with these agents is often treatment-limiting. The pathophysiology of this toxicity is not well delineated, and adverse effects to the central nervous system are often misdiagnosed by clinicians. This report reviews the preclinical and clinical literature describing the morbidity associated with these agents and suggests appropriate clinical management strategies and future directions for research.

Key Words: Neuropsychiatric Toxicity • Cytokines • Immunity

This article has been cited by other articles:

				J. R. Fann, C. M. Alfano, S. Roth-Roemer, W. J. Katon, and K. L. Syrjala Impact of Delirium on Cognition, Distress, and Health-Related Quality of Life After Hematopoietic Stem-Cell Transplantation J. Clin. Oncol., April 1, 2007; 25(10): 1223 - 1231. [Abstract] [Full Text] [PDF]

				O. A. Kalyoncu, D. Tan, H. Mirsal, O. Pektas, and M. Beyazyurek Major depressive disorder with psychotic features induced by interferon-{alpha} treatment for hepatitis C in a polydrug abuser J Psychopharmacol, January 1, 2005; 19(1): 102 - 105. [Abstract] [PDF]

				S. C. Matthews, M. P. Paulus, and J. E. Dimsdale Contribution of Functional Neuroimaging to Understanding Neuropsychiatric Side Effects of Interferon in Hepatitis C Psychosomatics, August 1, 2004; 45(4): 281 - 286. [Abstract] [Full Text] [PDF]

				C. U. Onyike, J. O. Bonner, C. G. Lyketsos, and G. J. Treisman Mania During Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin Am J Psychiatry, March 1, 2004; 161(3): 429 - 435. [Full Text] [PDF]

				L. Tamam, D. Yerdelen, and N. Ozpoyraz Psychosis Associated with Interferon Alfa Therapy for Chronic Hepatitis B Ann. Pharmacother., March 1, 2003; 37(3): 384 - 387. [Abstract] [Full Text] [PDF]

				K. Ademmer, M. Beutel, R. Bretzel, J. Clemens, and C. Reimer Suicidal Ideation With IFN-{alpha} and Ribavirin in a Patient With Hepatitis C Psychosomatics, August 1, 2001; 42(4): 365 - 367. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us